重组链激酶与尿激酶在急性心肌梗死溶栓治疗中的血管再通率的对比研究  

Comparative Study on the Recanalization Rate of Vascular Recombinant Streptokinase and Urokinase in Thrombolytic Therapy of Acute Myocardial Infarction

作　　者：陈明云[1] 熊莉娟[1] 李新宪[1] 冯杰[2] 庹田 

机构地区：[1]四川省广安市广安区中医院心内科,四川广安638001 [2]川北医学院附属医院心内科,四川南充637000 [3]四川省广安市人民医院心内科,四川广安638001

出　　处：《现代生物医学进展》2013年第26期5115-5118,共4页Progress in Modern Biomedicine

摘　　要：目的：比较国产重组链激酶（r-SK）与尿激酶（uK）在急性心肌梗死（AMI）溶栓中的血管再通率。方法：对68例诊断为AMI并进行溶栓治疗的患者进行临床分组治疗，观察组36例，对照组32例，观察组治疗给予r-SK，对照组治疗给予UK。观察两组患者血管再通率、住院并发症、不良反应以及30d病死率等。结果：观察组患者总血管再通率、小于6h血管再通率以及6-12h血管再通率均明显高于对照组（P〈0．05），不良反应方面，观察组用药后轻度出血、皮疹、低血压等与对照组比较无差异（P〉0．05）。30d病死率方面，观察组为11．11％，与对照组的15．63％比较无明显差异（P〉0．05）。结论：国产r-SK进行AMI溶栓的血管再通率高，不良反应明显优于UK，30d病死率与UK相似，值得临床应用。Objective： To compare the recanalization rate of vascular recombinant streptokinase （r-SK）and urokinase （UK） in thrombolytic therapy of acute myocardial infarction（AMI）. Methods： 68 cases were diagnosed as AMI patients. These patients were divid- ed into two groups, observation group （36 cases） received r-SK, and control group （32 cases） treated with UK therapy. Two groups were observed in patients with vascular recanalization rate, hospitalization, adverse reaction and complication of 30 d mortality rate. Results： The total vascular recanalization rate of the observation group was less than 6 h, and 6-12 h recanalization rate was significantly higher than that of control group （P〈0.05）.In adverse reaction, there was no significant difference between the two groups. After treatment mild bleeding, skin rash, hypotension were all observed in these two groups. （P〉0.05）. 30 d mortality rate, observation group was 11.11%, no significant difference compared with 15.63 % in control group （P〉0.05）. Conclusions： Domestic r-SK AMI thrombolytic reeanalization rate, adverse reaction was better than that of UK, 30 d mortality rate is similar with UK, it is worthy of clinical application.

关 键 词：国产重组链激酶 尿激酶 急性心肌梗死 溶栓 血管再通率 

分 类 号：R542.22[医药卫生—心血管疾病]